Trodusquemine is under clinical development by DepYmed and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Trodusquemine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Trodusquemine overview

Trodusquemine (MSI-1436) is under development for the treatment of metastatic breast cancer (HER2-positive breast cancer). The drug candidate is administered intravenously. It acts by targeting protein tyrosine phosphatase 1B (PTP1B). It was also under development for type 2 diabetes, obesity, acute myocardial infarction, spinal cord damage, central nervous system disorder, and cancer, chronic heart injury, acute kidney injury, Duchenne muscular dystrophy and skeletal muscle injury. 

DepYmed overview

DepYmed is a developer of therapeutic products for the treatment cancer and for the treatment wilson’s disease. The company is investigating PTP1B, a protein tyrosine phosphatase 1B for HER2-positive breast cancer and rett syndrome; and PTP1B inhibitors, a novel small molecule with copper chelating properties for the treatment wilson disease and cancer; It is also evaluating novel therapeutic for the treatment of triple negative breast cancer. DepYmed funding partners include Cold Spring Harbor Laboratory, Ohr Pharmaceutical Inc, Accelerate Long Island, Top Spin Fund LP and Jove Equity Partners LLC. DepYmed is headquartered in Farmingdale, New York, the US.

For a complete picture of Trodusquemine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.